title: In reply.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Sheeler
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Ackerman
authors.forename: Elliott
authors.initials: E
authors.lastname: Richelson
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Nelson
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Staab
authors.forename: Eric G
authors.initials: EG
authors.lastname: Tangalos
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Dieser
authors.forename: Julie L
authors.initials: JL
authors.lastname: Cunningham
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D015283:Citalopram / Q000009:adverse effects*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards*; D017751:Safety Management / Q000592:standards*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors